Here is how argenex SE (ARGX) and ANI Pharmaceuticals (ANIP) have performed compared to their sector so far this year.
ARGX, VZLA, and SBFG made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 31, 2024.
Argenx (ARGX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Here is how argenex SE (ARGX) and Canopy Growth Corporation (CGC) have performed compared to their sector so far this year.
Argenx (ARGX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Friday, the FDA approved Argenx SE's ARGX Vyvgart Hytrulo for use in patients with chronic inflammatory demyelinating polyneuropathy (CIDP).
Per argenx (ARGX), the label expansion to Vyvgart Hytrulo makes it the first FDA-approved medication with a novel mechanism of action to treat chronic inflammatory demyelinating polyneuropathy.
Argenx stock surged Monday after the FDA approved its drug, Vyvgart Hytrulo, for patients with an autoimmune condition known as CIDP.